Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2011

26 Nov 2011
Hotel Monte Málaga, Malaga, Spain
Recent advances in multiple myeloma therapy
Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimop...
Recent advances in multiple myeloma therapy ( Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimopoulos and Prof Thierry Facon )
14 Feb 2012
Recent advances in non-Hodgkin’s lymphoma therapy
Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter
Recent advances in non-Hodgkin’s lymphoma therapy ( Prof Mathias Rummel, Prof Umberto Vitolo, Prof Georg Hess, Prof Finbarr Cotter )
14 Feb 2012
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chro...
Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston
BTK inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma ( Prof Susan O’Brien - University of Texas MD Anderson Cancer Center, Houston )
9 Jan 2012
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell n...
Dr Laurie Sehn - University of British Columbia, Vancouver, Canada
Obinutuzumab with rituximab in patients with relapsed CD20 and indolent B-Cell non-hodgkin lymphoma (GAUSS) ( Dr Laurie Sehn - University of British Columbia, Vancouver, Canada )
9 Jan 2012
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma
Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group
ABVD chemo with radiation therapy for limited-stage hodgkin lymphoma ( Dr Ralph Meyer - National Cancer Institute of Canada Clinical Trials Group )
9 Jan 2012
Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESOR...
Prof Brad Kahl - University of Wisconsin, Madison, USA
Two rituximab dosing strategies for low tumour burden follicular lymphoma (RESORT) ( Prof Brad Kahl - University of Wisconsin, Madison, USA )
9 Jan 2012
Cereblon expression required for anti-myeloma activity of lenalidomide and pomal...
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
Cereblon expression required for anti-myeloma activity of lenalidomide and pomalidomide ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
9 Jan 2012
The latest for Multiple Myeloma
Prof Paul Richardson - Dana Farber Institute, Boston, USA
The latest for Multiple Myeloma ( Prof Paul Richardson - Dana Farber Institute, Boston, USA )
19 Dec 2011
Myelodysplastic syndrome drug development and combination therapy
Prof Valeria Santini – University of Florence, Italy
Myelodysplastic syndrome drug development and combination therapy ( Prof Valeria Santini – University of Florence, Italy )
19 Dec 2011
Clinical trial data on treatment of chronic lymphocytic leukaemia with PCI-32765...
Dr Susan O’Brien – MD Anderson Cancer Center, Houston, USA
Clinical trial data on treatment of chronic lymphocytic leukaemia with PCI-32765  ( Dr Susan O’Brien – MD Anderson Cancer Center, Houston, USA )
19 Dec 2011
Update and new perspectives in the management of MDS
Dr Mikkael Sekeres – Cleveland Clinic Taussig Institute, USA
Update and new perspectives in the management of MDS ( Dr Mikkael Sekeres – Cleveland Clinic Taussig Institute, USA )
19 Dec 2011
New data on aggressive B cell lymphoma
Dr Elaine Jaffe – National Cancer Institute, Bethesda, USA
New data on aggressive B cell lymphoma ( Dr Elaine Jaffe – National Cancer Institute, Bethesda, USA )
19 Dec 2011
Causes and drug development in ataxia telangiectasia
Dr Richard Gatti – David Geffen School of Medicine UCLA, USA
Causes and drug development in ataxia telangiectasia ( Dr Richard Gatti – David Geffen School of Medicine UCLA, USA )
19 Dec 2011
Update on the phase III VISTA trial
Dr Jesus San Miguel – University Hospital of Salamanca, Spain
Update on the phase III VISTA trial ( Dr Jesus San Miguel – University Hospital of Salamanca, Spain )
19 Dec 2011
Update on the development of proteasome inhibitors
Dr Philip McCarthy – Roswell Park Cancer Institute, USA
Update on the development of proteasome inhibitors ( Dr Philip McCarthy – Roswell Park Cancer Institute, USA )
19 Dec 2011
Romidepsin treatment in peripheral T cell lymphoma and subsets
Dr Francine Foss – Yale School of Medicine, Connecticut, USA
Romidepsin treatment in peripheral T cell lymphoma and subsets  ( Dr Francine Foss – Yale School of Medicine, Connecticut, USA )
19 Dec 2011
Optimal treatment schedule for pomalidomide in multiple myeloma
Prof Gareth Morgan, Royal Marsden Hospital, London, UK and Dr Xavier Leleu, Hôpi...
Optimal treatment schedule for pomalidomide in multiple myeloma ( Prof Gareth Morgan, Royal Marsden Hospital, London, UK and Dr Xavier Leleu, Hôpital Huriez, CHRU Lille, France )
19 Dec 2011
Indolent non-Hodgkin’s Lymphoma in 2011: A game changing year
Dr Mathias Rummel - University Hospital, Giessen, Germany, Prof John Gribben – B...
Indolent non-Hodgkin’s Lymphoma in 2011: A game changing year ( Dr Mathias Rummel - University Hospital, Giessen, Germany, Prof John Gribben – Barts and The London Trust Cancer Centre, UK and Prof Gilles Salles - Universite Claude Bernard Lyon, France  )
16 Dec 2011
The changing landscape for NHL treatment
Prof Bertrand Coiffier - Hospices Civils de Lyon, France
The changing landscape for NHL treatment ( Prof Bertrand Coiffier - Hospices Civils de Lyon, France )
16 Dec 2011
Novel agents and proteasome inhibitors in myeloma
Prof Michele Cavo - University of Bologna, Italy
Novel agents and proteasome inhibitors in myeloma  ( Prof Michele Cavo - University of Bologna, Italy )
14 Dec 2011
Advances in peripheral T-cell lymphoma
Prof John Gribben – Barts and The London Trust, London and Prof Bertrand Coiffie...
Advances in peripheral T-cell lymphoma ( Prof John Gribben – Barts and The London Trust, London and Prof Bertrand Coiffier - Hospices Civils de Lyon, France )
14 Dec 2011
Final results of the phase 3 VISTA trial: bortezomib-melphalan-prednisone (VMP) ...
Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain
Final results of the phase 3 VISTA trial: bortezomib-melphalan-prednisone (VMP) vs melphalan-prednisone (MP) for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain )
14 Dec 2011
Translational research and proteasome inhibitors in multiple myeloma
Prof Kenneth Anderson - Dana-Farber Cancer Institute, Boston, USA
Translational research and proteasome inhibitors in multiple myeloma ( Prof Kenneth Anderson - Dana-Farber Cancer Institute, Boston, USA )
14 Dec 2011
Developments in proteasome inhibitors, transplant and myeloma research
Dr Keith Stewart - Mayo Clinic, Scottsdale Arizona, USA
Developments in proteasome inhibitors, transplant and myeloma research ( Dr Keith Stewart - Mayo Clinic, Scottsdale Arizona, USA )
14 Dec 2011
Genomic study of acute myeloid leukaemia
Prof Gail Roboz - Weill Cornell Medical College, New York, USA
Genomic study of acute myeloid leukaemia ( Prof Gail Roboz - Weill Cornell Medical College, New York, USA )
13 Dec 2011
GIMEMA study compares bortezomib-thalidomide-dexamethasone with thalidomide-dexa...
Prof Michele Cavo - University of Bologna, Italy
GIMEMA study compares bortezomib-thalidomide-dexamethasone with thalidomide-dexamethasone prior to double autologous stem-cell transplantation ( Prof Michele Cavo - University of Bologna, Italy )
13 Dec 2011
Lenalidomide with melphalan + prednisone and lenalidomide maintenance for multip...
Prof Antonio Palumbo - University of Torino, Italy
Lenalidomide with melphalan + prednisone and lenalidomide maintenance for multiple myeloma ( Prof Antonio Palumbo - University of Torino, Italy )
13 Dec 2011